secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096171
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences Q2 net loss $8.5M; FDA Breakthrough Therapy for cytisinicline vaping cessation
--------------------------------------------------------------------------------

- Q2 net loss $8.5M vs $8.0M prior year; cash & equivalents $61.3M as of June 30, 2024.
- FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette cessation; no FDA-approved treatments exist.
- Refinanced up to $20M loan with SVB; maturity extended to Dec 1, 2027 from Aug 1, 2024.
- Initiated ORCA-OL trial for long-term cytisinicline exposure; over 50% of 650 participants enrolled.
- Included in Russell 3000 and Russell Microcap indexes effective July 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000095017024096171/0000950170-24-096171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000095017024096171/achv-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer